CENTESSA PHARMACEUTICALS PLC's ticker is CNTA and the CUSIP is 152309100. A total of 50 filers reported holding CENTESSA PHARMACEUTICALS PLC in Q2 2021. The put-call ratio across all filers is - and the average weighting 2.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,607,000 | -17.5% | 399,801 | 0.0% | 0.20% | -44.5% |
| Q2 2022 | $1,947,000 | -52.2% | 399,801 | -12.0% | 0.36% | -32.5% |
| Q1 2022 | $4,077,000 | -20.3% | 454,545 | 0.0% | 0.53% | +0.2% |
| Q4 2021 | $5,118,000 | -71.3% | 454,545 | -57.5% | 0.53% | -59.0% |
| Q3 2021 | $17,861,000 | -14.4% | 1,069,545 | +13.8% | 1.29% | -26.6% |
| Q2 2021 | $20,867,000 | – | 939,545 | – | 1.75% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 17,923,892 | $299,329,000 | 65.12% |
| Vida Ventures Advisors, LLC | 3,931,818 | $65,661,000 | 18.81% |
| Samsara BioCapital, LLC | 1,537,533 | $25,677,000 | 4.03% |
| VR Adviser, LLC | 1,127,272 | $18,825,000 | 2.42% |
| Logos Global Management LP | 1,069,545 | $17,861,000 | 1.29% |
| Cormorant Asset Management, LP | 1,727,273 | $28,724,000 | 1.17% |
| GENERAL ATLANTIC, L.P. | 9,681,818 | $161,686,000 | 0.95% |
| Affinity Asset Advisors, LLC | 203,183 | $3,393,000 | 0.86% |
| RA Capital Management | 3,577,094 | $59,737,000 | 0.83% |
| Boxer Capital, LLC | 1,334,227 | $22,282,000 | 0.78% |